Filed by the Registrant
|
o
|
Filed by a Party other than the Registrant
|
x
|
o
|
Preliminary Proxy Statement
|
o
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
o
|
Definitive Proxy Statement
|
x
|
Definitive Additional Materials
|
o
|
Soliciting Material Pursuant to §240.14a-12
|
x
|
No fee required.
|
o
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
|
|
1)
|
Title of each class of securities to which transaction applies:
|
|
2)
|
Aggregate number of securities to which transaction applies:
|
|
3)
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
|
|
4)
|
Proposed maximum aggregate value of transaction:
|
|
5)
|
Total fee paid:
|
o
|
Fee paid previously with preliminary materials.
|
o
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
|
|
1)
|
Amount Previously Paid:
|
|
2)
|
Form, Schedule or Registration Statement No.:
|
|
3)
|
Filing Party:
|
|
4)
|
Date Filed:
|
|
·
|
Overseen a flawed acquisition strategy -- only two deals in two years, one with revenues of less than $2 million, and none since July 2011;
|
|
·
|
Failed to capitalize on the Company’s only significant asset -- $900 million in net operating losses, or NOLs;
|
|
·
|
Failed to provide stockholders with current financial information for almost 2 years prior to its delayed SEC filings;
|
|
·
|
Misaligned performance and compensation; and
|
|
·
|
Overseen a 12% decrease in assets and a 30% decrease in stockholders’ equity; and
|
|
·
|
Abused the poison pill in an effort to entrench themselves and thwart your ability to choose the future direction of the Company through a stockholder vote.
|
|
·
|
Stockholders have little chance of realizing any value from the NOLs under management’s plan if the NOLs are saved to shelter the Company’s possible (though improbable) earnings in 2020 or 2030, as management seems committed to doing.
|
|
·
|
With no present material taxable income the Company cannot benefit from the NOLs.
|
|
·
|
In fact, management has already acknowledged in the Company’s financial statements that sufficient uncertainty exists as to the realizability of the value of the NOLs.
|
|
·
|
Extensive experience leading companies as CEOs;
|
|
·
|
Significant track records as public company Board members;
|
|
·
|
Strong backgrounds in the financial services industry;
|
|
·
|
Expertise and backgrounds in corporate governance;
|
|
·
|
A commitment to working solely in the interest of stockholders with a plan to unlock the value of Signature’s significant asset in a timely manner; and
|
|
·
|
A commitment to strong corporate governance and a soundly functioning Board to protect stockholder interests.
|
|
·
|
A large number of small transactions in multiple business sectors will create an operating company even more complex than what the Board and management have already fashioned in unrelated industries in which they have no historical experience or expertise. For example, as a result of management’s initial acquisitions, the Company now faces business challenges in the cosmetics and electronic circuit breaker industries.
|
|
·
|
Many small transactions, as compared to a few larger targeted deals, will likely take a lot longer to close and an even longer time to utilize the NOLs, if ever.
|
|
·
|
Small transactions carry significant risk that they cannot be financed or will not close or that management will not be able to conduct proper due diligence on the multiplicity of opportunities.
|
|
·
|
Small transactions potentially reduce transparency by obscuring, in consolidation, financial reporting and management accountability with multiple subsidiary levels.
|
If you have any questions regarding your proxy,
|
or need assistance in voting your shares, please call:
|
105 Madison Avenue
|
New York, New York 10016
|
(212) 929-5500 (Call Collect)
|
proxy@mackenziepartners.com
|
or
|
CALL TOLL FREE (800) 322-2885
|